Sana Biotechnology (SANA) Total Liabilities (2020 - 2026)
Sana Biotechnology (SANA) posted Total Liabilities of $254.4 million for Q1 2026, down 0.65% sequentially from $256.0 million in Q4 2025, and up 7.6% YoY from $236.4 million in Q1 2025.
Sana Biotechnology (SANA) Total Liabilities (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Total Liabilities for 7 years, with the latest figure at $254.4 million in Q1 2026.
- Quarterly Total Liabilities rose 7.6% year-over-year to $254.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $254.4 million (up 7.6% YoY) and the FY2025 annual result came in at $256.0 million, up 2.19% from the prior year.
- Total Liabilities declined to $254.4 million in Q1 2026 per SANA's latest filing, from $256.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $352.1 million in Q2 2023 and troughed at $236.4 million in Q1 2025.
- A 5-year average of $286.8 million and a median of $277.8 million in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities slipped 22.81% in 2025, then increased 7.6% in 2026.
- Over 5 years, Total Liabilities stood at $323.4 million in 2022, then retreated by 14.1% to $277.8 million in 2023, then retreated by 9.82% to $250.5 million in 2024, then grew by 2.19% to $256.0 million in 2025, then declined by 0.65% to $254.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $254.4 million, $256.0 million, and $240.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Sana Biotechnology | 1.06 Bn | 1.06 Bn | - | 276.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 276.95 Mn |
| Mar 31, 2026 | 254.35 Mn |
| Dec 31, 2025 | 256.01 Mn |
| Sep 30, 2025 | 240.12 Mn |
| Jun 30, 2025 | 239.09 Mn |
| Mar 31, 2025 | 236.39 Mn |
| Dec 31, 2024 | 250.52 Mn |
| Sep 30, 2024 | 266.91 Mn |
| Jun 30, 2024 | 279.02 Mn |
| Mar 31, 2024 | 306.24 Mn |
| Dec 31, 2023 | 277.79 Mn |
| Sep 30, 2023 | 265.59 Mn |
| Jun 30, 2023 | 352.12 Mn |
| Mar 31, 2023 | 318.67 Mn |
| Dec 31, 2022 | 323.41 Mn |
| Sep 30, 2022 | 332.08 Mn |
| Jun 30, 2022 | 331.58 Mn |
| Mar 31, 2022 | 345.96 Mn |
| Dec 31, 2021 | 400.91 Mn |
| Sep 30, 2021 | 402.67 Mn |